Literature DB >> 28522262

Transglutaminase 2 modulation of NF-κB signaling in astrocytes is independent of its ability to mediate astrocytic viability in ischemic injury.

Julianne Feola1, Alan Barton2, Abdullah Akbar3, Jeffrey Keillor4, Gail V W Johnson5.   

Abstract

Transglutaminase 2 (TG2) is a multifunctional protein that can contribute to cell death and cell survival processes in a variety of disease contexts. Within the brain, TG2 has been shown to promote cell death in ischemic injury when expressed in astrocytes (Colak and Johnson, 2012). However, the specific functions and characteristics of astrocytic TG2 that mediate this effect are largely unknown. Therefore, the goal of this study was to investigate the role of astrocytic TG2 in mediating cellular viability processes in the context of ischemic injury, with a specific focus on its contributions to intracellular signaling cascades. We show that, in response to oxygen/glucose deprivation (OGD), acute lentiviral-mediated knockdown of TG2, as well as inhibition with an irreversible TG2 inhibitor, enhances cell survival. We also show that TG2 depletion increases nuclear factor-κB (NF-κB) signaling, whereas inhibition reduces NF-κB activity. Despite its clear contribution to NF-κB signaling, however, TG2 modulation of NF-κB signaling is not likely to be a major contributor to its ability to mediate astrocytic viability in this context. Overall, the results of this study provide insight into the role of TG2 in astrocytes and suggest possible avenues for future study of the relationship between astrocytic TG2 and ischemic injury.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Astrocyte; ERK1/2; Ischemia; JNK; NF-κB; Oxygen/glucose deprivation; Transamidation; Transglutaminase 2; Viability; p38

Mesh:

Substances:

Year:  2017        PMID: 28522262      PMCID: PMC5525061          DOI: 10.1016/j.brainres.2017.05.009

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  70 in total

Review 1.  Transglutaminase 2: a molecular Swiss army knife.

Authors:  Soner Gundemir; Gozde Colak; Janusz Tucholski; Gail V W Johnson
Journal:  Biochim Biophys Acta       Date:  2011-10-10

Review 2.  NF-kappaB in neuronal plasticity and neurodegenerative disorders.

Authors:  M P Mattson; S Camandola
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

3.  Stimulating ERK/PI3K/NFκB signaling pathways upon activation of mGluR2/3 restores OGD-induced impairment in glutamate clearance in astrocytes.

Authors:  Chia-Ho Lin; Jie-Ru You; Kai-Che Wei; Po-Wu Gean
Journal:  Eur J Neurosci       Date:  2013-10-16       Impact factor: 3.386

Review 4.  Brain injury: prolonged induction of transcription factors.

Authors:  K R Pennypacker; C A Kassed; S Eidizadeh; J P O'Callaghan
Journal:  Acta Neurobiol Exp (Wars)       Date:  2000       Impact factor: 1.579

5.  Appearance of tissue transglutaminase in astrocytes in multiple sclerosis lesions: a role in cell adhesion and migration?

Authors:  Miriam E van Strien; Benjamin Drukarch; John G Bol; Paul van der Valk; Jack van Horssen; Wouter H Gerritsen; John J Breve; Anne-Marie van Dam
Journal:  Brain Pathol       Date:  2010-08-20       Impact factor: 6.508

6.  Transglutaminase and polyamination of tubulin: posttranslational modification for stabilizing axonal microtubules.

Authors:  Yuyu Song; Laura L Kirkpatrick; Alexander B Schilling; Donald L Helseth; Nicolas Chabot; Jeffrey W Keillor; Gail V W Johnson; Scott T Brady
Journal:  Neuron       Date:  2013-04-10       Impact factor: 17.173

7.  Tissue transglutaminase triggers oligomerization and activation of dual leucine zipper-bearing kinase in calphostin C-treated cells to facilitate apoptosis.

Authors:  K Robitaille; A Daviau; J Tucholski; G V W Johnson; C Rancourt; R Blouin
Journal:  Cell Death Differ       Date:  2004-05       Impact factor: 15.828

Review 8.  Post-ischemic brain damage: NF-kappaB dimer heterogeneity as a molecular determinant of neuron vulnerability.

Authors:  Marina Pizzi; Ilenia Sarnico; Annamaria Lanzillotta; Leontino Battistin; PierFranco Spano
Journal:  FEBS J       Date:  2009-01       Impact factor: 5.542

9.  Transamidation by transglutaminase 2 transforms S100A11 calgranulin into a procatabolic cytokine for chondrocytes.

Authors:  Denise L Cecil; Robert Terkeltaub
Journal:  J Immunol       Date:  2008-06-15       Impact factor: 5.422

10.  Extracellular tissue transglutaminase activates noncanonical NF-κB signaling and promotes metastasis in ovarian cancer.

Authors:  Bakhtiyor Yakubov; Bhadrani Chelladurai; Jordan Schmitt; Robert Emerson; John J Turchi; Daniela Matei
Journal:  Neoplasia       Date:  2013-06       Impact factor: 5.715

View more
  6 in total

1.  Subcellular localization patterns of transglutaminase 2 in astrocytes and neurons are differentially altered by hypoxia.

Authors:  Laura Yunes-Medina; Julianne Feola; Gail V W Johnson
Journal:  Neuroreport       Date:  2017-12-13       Impact factor: 1.837

Review 2.  Transglutaminase 2: Friend or foe? The discordant role in neurons and astrocytes.

Authors:  Breandan R Quinn; Laura Yunes-Medina; Gail V W Johnson
Journal:  J Neurosci Res       Date:  2018-03-23       Impact factor: 4.164

3.  Depletion of transglutaminase 2 in neurons alters expression of extracellular matrix and signal transduction genes and compromises cell viability.

Authors:  Laura Yunes-Medina; Alex Paciorkowski; Yan Nuzbrokh; Gail V W Johnson
Journal:  Mol Cell Neurosci       Date:  2017-11-29       Impact factor: 4.314

4.  Depletion of astrocytic transglutaminase 2 improves injury outcomes.

Authors:  Alina Monteagudo; Julianne Feola; Heather Natola; Changyi Ji; Christoph Pröschel; Gail V W Johnson
Journal:  Mol Cell Neurosci       Date:  2018-06-30       Impact factor: 4.314

5.  MicroRNA‑451 relieves inflammation in cerebral ischemia‑reperfusion via the Toll‑like receptor 4/MyD88/NF‑κB signaling pathway.

Authors:  Wenyan Li; Minghao Dong; Liangzhao Chu; Luqian Feng; Xiaochuan Sun
Journal:  Mol Med Rep       Date:  2019-08-12       Impact factor: 2.952

6.  Deletion or Inhibition of Astrocytic Transglutaminase 2 Promotes Functional Recovery after Spinal Cord Injury.

Authors:  Anissa Elahi; Jacen Emerson; Jacob Rudlong; Jeffrey W Keillor; Garrick Salois; Adam Visca; Peter Girardi; Gail V W Johnson; Christoph Pröschel
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.